GGrantIndex
← Leaderboards

Wolfgang Christoph Winkelmayer

Baylor College Of Medicine

$6,066,937
Attributed
$6,066,937
Total exposure
4
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $927.3K · FY200923
$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$6,066,937 · 4

By mechanism

R01$5,590,687 · 2
R21$466,250 · 1
R13$10,000 · 1

Top collaborators

No co-investigators on record.

Most similar at Baylor College Of Medicine

Same institution · by research overlap

Others in their field

Top investigators on “Interest

Research focus

InterestDialysis ProcedureCardiovascular SystemEnd Stage Renal FailureFundingKidney DiseasesMedicarePatient PopulationAmericanKidneyCessation Of LifePharmaceutical PreparationsHemoglobinStrokeDiagnosisEventDatabasesProviderOlder PatientAtrial FibrillationRenal DialysisPatternLaboratoriesDiabetes Mellitus

Grant awards (15)

The Atrial Fibrillation-Factor Identification to Risk Modification Study in CKD/ESRD$515,582
R01 · FY2023 · DK · contact PI
The Atrial Fibrillation-Factor Identification to Risk Modification Study in CKD/ESRD$525,282
R01 · FY2022 · DK · contact PI
The Atrial Fibrillation-Factor Identification to Risk Modification Study in CKD/ESRD$688,545
R01 · FY2021 · DK · contact PI
The Atrial Fibrillation-Factor Identification to Risk Modification Study in CKD/ESRD$648,717
R01 · FY2020 · DK · contact PI
The Atrial Fibrillation - Factor Identification to Risk Modification Study in HD$450,515
R01 · FY2015 · DK · contact PI
The Atrial Fibrillation - Factor Identification to Risk Modification Study in HD$465,609
R01 · FY2014 · DK · contact PI
The Atrial Fibrillation - Factor Identification to Risk Modification Study in HD$462,674
R01 · FY2013 · DK · contact PI
Comparative Effectiveness and Safety of Newer Agents for Anemia Treatment in HD$331,645
R01 · FY2013 · DK · contact PI
Comparative Effectiveness and Safety of Newer Agents for Anemia Treatment in HD$82,919
R01 · FY2013 · DK · contact PI
The Atrial Fibrillation - Factor Identification to Risk Modification Study in HD$504,227
R01 · FY2012 · DK · contact PI
Comparative Effectiveness and Safety of Newer Agents for Anemia Treatment in HD$413,071
R01 · FY2012 · DK · contact PI
2012 ASN Update on Patient Centered Outcomes Research in Kidney Disease$10,000
R13 · FY2012 · DK · contact PI
Comparative Effectiveness and Safety of Newer Agents for Anemia Treatment in HD$501,901
R01 · FY2011 · DK · contact PI
Warfarin Use in ESRD Patients with Atrial Fibrillation: Risks, Benefits, Behavior$200,000
R21 · FY2010 · DK · contact PI
Warfarin Use in ESRD Patients with Atrial Fibrillation: Risks, Benefits, Behavior$266,250
R21 · FY2009 · DK · contact PI